Plus Therapeutics signs AI deal with Ephemeral

Plus Therapeutics has signed an agreement with Ephemeral Technologies to develop an AI execution platform for CNS oncology. The platform is intended to integrate therapeutic, diagnostic, and bioinformatics datasets across Plus’ CNS oncology programs.

Ephemeral was founded by former co-heads of Palantir Technologies’ U.S. healthcare business. Plus said the company will help assess and implement AI-enabled data infrastructure for complex CNS oncology datasets.

Longitudinal data from Plus’ therapeutic and diagnostic workflows will be organized and analyzed through the platform, according to the announcement. No financial terms were disclosed.

Beginning in 2026, Plus said it expects the partnership to support laboratory and clinical operating efficiency and workflows. Longer-term planned uses include operational decision support, translational analytics, treatment-response analytics, patient stratification, precision oncology, pharmaceutical collaborations, and real-world evidence initiatives.

Plus Therapeutics is a Houston-based clinical-stage company developing targeted radiotherapeutics for central nervous system cancers. Its lead programs include leptomeningeal metastases and recurrent glioblastoma.

CNSide Diagnostics, a wholly owned Plus subsidiary, develops laboratory-developed tests including CNSide, a cerebrospinal fluid assay platform for analyzing tumor cells that have metastasized to the central nervous system.